来源:药渡撰文:Pharmadeep编辑:维他命2025年4月25日,康方生物宣布其自主研发的PD-1单抗药物派安普利单抗注射液(商品名:安尼可®)获美国FDA批准上市,用于治疗复发或转移性鼻咽癌(NPC)的一线治疗和以铂类为基础的至少一线化疗治疗进展后的2项适应症。这标志着派安普利单抗成为康方生物首个在美国获批上市的创新生物药,也代表着中国药企全过程独立主导的创新药首次获得FDA批准,具有重要的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.